Karyopharm Therapeutics is a commercial-stage pharmaceutical enterprise focused on discovering, developing, and commercializing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. By leveraging its pioneering selective inhibitor of nuclear export platform, the company designs therapeutics that reactivate tumor suppressor proteins and regulate inflammatory pathways, addressing severe unmet medical needs in oncology and rare conditions.